ストックスクリーナーアプリを入手
0.295
6.23%
-0.0196
アフターアワーズ：
.30
0.005
+1.69%
前日終値:
$0.3146
開ける：
$0.31
24時間の取引高:
476.21K
Relative Volume:
0.51
時価総額：
$2.47M
収益：
-
当期純損益:
$-15.52M
株価収益率:
-0.5363
EPS:
-0.5501
ネットキャッシュフロー:
$-16.61M
1週間 パフォーマンス:
-18.06%
1か月 パフォーマンス:
-61.12%
6か月 パフォーマンス:
-86.28%
1年 パフォーマンス:
-98.24%
1日の値動き範囲:
$0.295
$0.318
1週間の範囲:
$0.295
$0.375
52週間の値動き範囲:
$0.295
$25.26
Revelation Biosciences Inc Stock (REVB) Company Profile
名前
Revelation Biosciences Inc
セクター
電話
650-800-3717
住所
4660 LAJOLLA VILLAGE DRIVE, SAN DIEGO
REVB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
REVB
Revelation Biosciences Inc
|
0.295 | 2.47M | 0 | -15.52M | -16.61M | -18.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Revelation Biosciences Inc (REVB) 最新ニュース
Revelation Biosciences stock hits 52-week low at $0.32 - Investing.com
Pre-market Movers: EWTX, TNXP, LNSR, VRDN... - RTTNews
Revelation Biosciences files for secondary offering of common stock - MSN
Revelation Biosciences stock hits 52-week low at $0.42 - Investing.com India
Revelation Biosciences stock hits 52-week low at $0.42 By Investing.com - Investing.com UK
Reviewing Emmaus Life Sciences (OTCMKTS:EMMA) and Revelation Biosciences (NASDAQ:REVB) - Defense World
Revelation Biosciences stock hits 52-week low at $0.7 By Investing.com - Investing.com South Africa
United States shares mixed at close of trade; Dow Jones Industrial Average down 0.17% - Investing.com India
Revelation Biosciences stock hits 52-week low at $0.7 - Investing.com India
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.17% - Investing.com
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.17% - Investing.com UK
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Revelation Biosciences Secures $4M Through Warrant Exercise, Issues New Warrants - StockTitan
FDA approves Revelation Biosciences' drug trial for CKD By Investing.com - Investing.com Nigeria
Best Penny Stocks for Today (Charts Updated Daily) - Benzinga
Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND - Marketscreener.com
FDA approves Revelation Biosciences' drug trial for CKD - Investing.com
Revelation Bio's Kidney Disease Drug Gemini Receives FDA IND Approval for Phase 1b Trial - StockTitan
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.14% - MSN
Warning: REVB is at high risk of performing badly - MSN
Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply - BioSpace
Revelation Bio Achieves Key Manufacturing Milestone for Kidney Disease Drug Trial | REVB Stock News - StockTitan
United Therapeutics (UTHR) Stock Dips Amid Broader Biotech Indus - GuruFocus.com
Allergic Rhinitis Treatment Market Size in the 7MM is expected to Grow by 2034 | DelveInsight - Barchart
REVB: Good Expense Control as Company Prepares for Trials - Research Tree
Pre-market Movers: REVB, CDIO, SMLR, DWTX... - RTTNews
Why Revelation Biosciences Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket - Benzinga
REVB Results Set Stage for Future Growth - Yahoo Finance
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024 - sharewise
Revelation Biosciences Inc expected to post a loss of $2.29 a shareEarnings Preview - XM
Revelation Bio Q3 Loss Narrows to $2.2M, Secures $3.8M from Warrants Amid Cash Decline | REVB Stock News - StockTitan
Revelation Biosciences Inc (REVB) Quarterly 10-Q Report - Quartzy
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.14% - MSN
Revelation Biosciences faces Nasdaq delisting over noncompliance - Investing.com India
United States shares lower at close of trade; Dow Jones Industrial Average down 0.43% - MSN
ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City - The Manila Times
A better buy-in window may exist right now for Revelation Biosciences Inc (REVB) - SETE News
Revelation Biosciences Inc Inc. (REVB) Price Performance: A Guide to Technical Indicators - The InvestChronicle
Farallon Capital Management LLC Boosts Stake in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Revolution Medicines added to Analyst Focus List at JPMorgan - TipRanks
Revelation Biosciences’ Gemini Induces Dose Dependent Significant Increases in IL-10 - Morningstar
Revolution Medicines, Inc. (NASDAQ:RVMD) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Revolution Medicines (NASDAQ:RVMD) Trading Down 6.1% - MarketBeat
A stock that deserves closer examination: Revelation Biosciences Inc (REVB) - US Post News
Revance Therapeutics Shares Fall on Crown Labs Deal Delay - MarketWatch
Financial Fitness Check: Examining Revelation Biosciences Inc (REVB)’s Key Ratios - The Dwinnex
Revance Therapeutics plunges as Crown Labs tender offer delayed amid Teoxane dispute - Seeking Alpha
Revolve Group (NYSE:RVLV) Reaches New 1-Year High at $25.96 - Defense World
Revelation Biosciences stock hits 52-week low at $0.78 - Investing.com India
Revelation Biosciences stock hits 52-week low at $0.78 By Investing.com - Investing.com Australia
Revolution Medicines executive sells over $500k in company stock By Investing.com - Investing.com Canada
Revelation Biosciences Inc (REVB) 財務データ
収益
当期純利益
現金流量
EPS
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):